Search

Your search keyword '"Gomella, Leonard G."' showing total 1,359 results
Start Over Author "Gomella, Leonard G."

Refine your results

more »

more »

more »

more »
1,359 results on '"Gomella, Leonard G."'

1. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing

Author

Leader, Amy E., Rebbeck, Timothy R., Oh, William K., Patel, Alpa V., Winer, Eric P., Bailey, LeeAnn O., Gomella, Leonard G., Lumpkins, Crystal Y., Garraway, Isla P., Aiello, Lisa B., Baskin, Monica L., Cheng, Heather H., Cooney, Kathleen A., Ganzak, Amanda, George, Daniel J., Halabi, Susan, Hathaway, Feighanne, Healy, Claire, Kim, Joseph W., Leapman, Michael S., Loeb, Stacy, Maxwell, Kara N., McNair, Christopher, Morgan, Todd M., Prindeville, Breanne, Soule, Howard R., Steward, Whitney L., Suttiratana, Sakinah C., Taplin, Mary-Ellen, Yamoah, Kosj, Fortune, Thierry, Bennett, Kris, Blanding-Godbolt, Joshua, Gross, Laura, and Giri, Veda N.

Published
2024
Full Text
View/download PDF

2. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial

Author

Ross, Ashley E., Zhang, Jingbin, Huang, Huei-Chung, Yamashita, Rikiya, Keim-Malpass, Jessica, Simko, Jeffry P., DeVries, Sandy, Morgan, Todd M., Souhami, Luis, Dobelbower, Michael C., McGinnis, L. Scott, Jones, Christopher U., Dess, Robert T., Zeitzer, Kenneth L., Choi, Kwang, Hartford, Alan C., Michalski, Jeff M., Raben, Adam, Gomella, Leonard G., Sartor, A. Oliver, Rosenthal, Seth A., Sandler, Howard M., Spratt, Daniel E., Pugh, Stephanie L., Mohamad, Osama, Esteva, Andre, Chen, Emmalyn, Schaeffer, Edward M., Tran, Phuoc T., and Feng, Felix Y.

Published
2024
Full Text
View/download PDF

4. Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs

Author

Russo, Jessica, McDougall, Carey, Bowler, Nicholas, Shimada, Ayako, Gross, Laura, Hyatt, Colette, Kelly, William K, Calvaresi, Anne, Handley, Nathan R, Hirsch, Irvin H, Izes, Joseph K, Lallas, Costas D, Mann, Mark, Mark, James Ryan, Mille, Patrick J, Preate, Donald, Trabulsi, Edouard J, Tsang, Miranda, Chandrasekar, Thenappan, Weiner, Perry R, Gomella, Leonard G, and Giri, Veda N

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Clinical Research, Urologic Diseases, Prostate Cancer, Cancer, Genetics, 7.1 Individual care needs, Management of diseases and conditions, Good Health and Well Being, Aged, Chi-Square Distribution, Choice Behavior, Genetic Counseling, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Patient Education as Topic, Prostatic Neoplasms, Surveys and Questionnaires, Oncology and carcinogenesis
Abstract

PurposeGermline testing (GT) for prostate cancer (PCA) is now central to treatment and hereditary cancer assessment. With rising demand for and shortage of genetic counseling (GC), tools to deliver pretest informed consent across practice settings are needed to improve access to GT and precision care. Here, we report on Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWER), a patient-choice study for pretest video-based genetic education (VBGE) versus GC to inform urgent practice needs.Patients and methodsMen with PCA or at risk for PCA (family history of PCA) were eligible and could choose pretest VBGE or GC. Outcomes included decisional conflict for GT, change in genetics knowledge, satisfaction, and intention to share results with family and/or providers. Descriptive statistics summarized results with counts and percentages for categorical variables and mean ± standard deviation for continuous variables. Data were compared with Fisher's exact, chi-squared, or Wilcoxon two-sample tests. Mean change in genetics knowledge was compared with t tests. The significance level was set a priori at .05.ResultsData on the first 127 participants were analyzed. Characteristics were White (85.8%), bachelor's degree (66.9%), and PCA diagnosis (90.6%). The majority chose VBGE (71%) versus GC (29%; P < .001). No differences were observed in decisional conflict for GT or satisfaction. Cancer genetics knowledge improved in both groups without significant difference (+0.9 VBGE, +1.8 GC, P = .056). Men who chose VBGE had higher intention to share GT results (96.4% VBGE v 86.4% GC, P = .02). Both groups had high rates of GT uptake (VBGE 94.4%, GC 92%).ConclusionA substantial proportion of men opted for pretest VBGE, with comparable patient-reported outcomes and uptake of GT. The results support the use of pretest video to address the critical GC shortage in the precision era.

Published
2021

5. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing

Author

Loeb, Stacy, Keith, Scott W., Cheng, Heather H., Leader, Amy E., Gross, Laura, Sanchez Nolasco, Tatiana, Byrne, Nataliya, Hartman, Rebecca, Brown, Lauren H., Pieczonka, Christopher Michael, Gomella, Leonard G., Kelly, William Kevin, Lallas, Costas D., Handley, Nathan, Mille, Patrick Johnston, Mark, James Ryan, Brown, Gordon Andrew, Chopra, Sameer, McClellan, Alexandra, Wise, David R., Hollifield, Lucas, and Giri, Veda N.

Published
2024
Full Text
View/download PDF

6. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial

Author

Sartor, Oliver, Karrison, Theodore G., Sandler, Howard M., Gomella, Leonard G., Amin, Mahul B., Purdy, James, Michalski, Jeff M., Garzotto, Mark G., Pervez, Nadeem, Balogh, Alexander G., Rodrigues, George B., Souhami, Luis, Reaume, M. Neil, Williams, Scott G., Hannan, Raquibul, Jones, Christopher U., Horwitz, Eric M., Rodgers, Joseph P., Feng, Felix Y., and Rosenthal, Seth A.

Published
2023
Full Text
View/download PDF

7. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Author

Giri, Veda N, Knudsen, Karen E, Kelly, William K, Cheng, Heather H, Cooney, Kathleen A, Cookson, Michael S, Dahut, William, Weissman, Scott, Soule, Howard R, Petrylak, Daniel P, Dicker, Adam P, AlDubayan, Saud H, Toland, Amanda E, Pritchard, Colin C, Pettaway, Curtis A, Daly, Mary B, Mohler, James L, Parsons, J Kellogg, Carroll, Peter R, Pilarski, Robert, Blanco, Amie, Woodson, Ashley, Rahm, Alanna, Taplin, Mary-Ellen, Polascik, Thomas J, Helfand, Brian T, Hyatt, Colette, Morgans, Alicia K, Feng, Felix, Mullane, Michael, Powers, Jacqueline, Concepcion, Raoul, Lin, Daniel W, Wender, Richard, Mark, James Ryan, Costello, Anthony, Burnett, Arthur L, Sartor, Oliver, Isaacs, William B, Xu, Jianfeng, Weitzel, Jeffrey, Andriole, Gerald L, Beltran, Himisha, Briganti, Alberto, Byrne, Lindsey, Calvaresi, Anne, Chandrasekar, Thenappan, Chen, David YT, Den, Robert B, Dobi, Albert, Crawford, E David, Eastham, James, Eggener, Scott, Freedman, Matthew L, Garnick, Marc, Gomella, Patrick T, Handley, Nathan, Hurwitz, Mark D, Izes, Joseph, Karnes, R Jeffrey, Lallas, Costas, Languino, Lucia, Loeb, Stacy, Lopez, Ana Maria, Loughlin, Kevin R, Lu-Yao, Grace, Malkowicz, S Bruce, Mann, Mark, Mille, Patrick, Miner, Martin M, Morgan, Todd, Moreno, Jose, Mucci, Lorelei, Myers, Ronald E, Nielsen, Sarah M, O'Neil, Brock, Pinover, Wayne, Pinto, Peter, Poage, Wendy, Raj, Ganesh V, Rebbeck, Timothy R, Ryan, Charles, Sandler, Howard, Schiewer, Matthew, Scott, E Michael D, Szymaniak, Brittany, Tester, William, Trabulsi, Edouard J, Vapiwala, Neha, Yu, Evan Y, Zeigler-Johnson, Charnita, and Gomella, Leonard G

Subjects
Biotechnology, Aging, Genetics, Prevention, Clinical Research, Cancer, Prostate Cancer, Genetic Testing, Urologic Diseases, Health Services, Good Health and Well Being, Germ-Line Mutation, History, 20th Century, Humans, Male, Prostatic Neoplasms, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeGermline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services.MethodsA multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider).ResultsLarge germline panels and somatic testing were recommended for metastatic PCA. Reflex testing-initial testing of priority genes followed by expanded testing-was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches.ConclusionThis multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.

Published
2020

9. Volumetric Quantitative Contrast-enhanced Ultrasonography Evaluation of Complex Renal Cysts: An Adjunctive Metric to the Bosniak Classification System to Predict Malignancy

Author

Chandrasekar, Thenappan, Clark, Cassra B., Gomella, Andrew, Wessner, Corinne E., Wang, Shuo, Nam, Kibo, Liu, Ji-Bin, Forsberg, Flemming, Lyshchik, Andrej, Halpern, Ethan, Mark, James R., Lallas, Costas D., Gomella, Leonard G., Kania, Leann, Trabulsi, Edouard J., and Eisenbrey, John R.

Published
2023
Full Text
View/download PDF

11. Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario

Author

Leong, Joon Yau, Herrera-Caceres, Jaime O, Goldberg, Hanan, Tham, Elwin, Teplitsky, Seth, Gomella, Leonard G, Fleshner, Neil E, Lallas, Costas D, Trabulsi, Edouard J, and Chandrasekar, Thenappan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Briganti, mpMRI, targeted biopsy, MSKCC, nomogram, radical prostatectomy
Abstract

BackgroundWe examine the practical application of multiparametric MRI (mpMRI) prostate biopsy data using established pre-RP nomograms and its potential implications on RP intraoperative decision-making. We hypothesize that current nomograms are suboptimal in predicting outcomes with mpMRI targeted biopsy (TBx) data.Materials and methodsPatients who underwent mpMRI-based TBx prior to RP were assessed using the MSKCC and Briganti nomograms with the following iterations: (1) Targeted (T) (targeted only), (2) Targeted and Systematic (TS) and (3) Targeted Augmented (TA) (targeted core data; assumed negative systematic cores for 12 total cores). Nomogram outcomes, lymph node involvement (LNI), extracapsular extension (ECE), organ-confined disease (OCD), seminal vesicle invasion (SVI), were compared across iterations. Clinically significant impact on management was defined as a change in LNI risk above or below 2% (Δ2) or 5% (Δ5).ResultsA total of 217 men met inclusion criteria. Overall, the TA iteration had more conservative nomogram outcomes than the T. Moreover, TA better predicted RP pathology for all four outcomes when compared with the T. In the entire cohort, Δ2 and Δ5 were 16.6-25.8% and 20.3-39.2%, respectively. In the subset of 190 patients with targeted and systematic cores, TA was a better approximation of TS outcomes than T in 71% (MSKCC) and 82% (Briganti) of patients.ConclusionIn established pre-RP nomograms, mpMRI-based TBx often yield variable and discordant results when compared with systematic biopsies. Future nomograms must better incorporate mpMRI TBx core data. In the interim, augmenting TBx data may serve to bridge the gap.

Published
2019

12. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing

Author

Loeb, Stacy, Cheng, Heather H., Leader, Amy, Gross, Laura, Nolasco, Tatiana Sanchez, Byrne, Nataliya, Wise, David R., Hollifield, Lucas, Brown, Lauren H., Slater, Elias, Pieczonka, Christopher, Gomella, Leonard G., Kelly, William K., Trabulsi, Edouard J., Handley, Nathan, Lallas, Costas D., Chandrasekar, Thenappan, Mille, Patrick, Mann, Mark, Mark, James Ryan, Brown, Gordon, Chopra, Sameer, Wasserman, Jenna, Phillips, Jade, Somers, Patrick, and Giri, Veda N.

Published
2022
Full Text
View/download PDF

13. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial

Author

Pollack, Alan, Karrison, Theodore G, Balogh, Alexander G, Gomella, Leonard G, Low, Daniel A, Bruner, Deborah W, Wefel, Jeffrey S, Martin, Andre-Guy, Michalski, Jeff M, Angyalfi, Steve J, Lukka, Himanshu, Faria, Sergio L, Rodrigues, George B, Beauchemin, Marie-Claude, Lee, R Jeffrey, Seaward, Samantha A, Allen, Aaron M, Monitto, Drew C, Seiferheld, Wendy, Sartor, Oliver, Feng, Felix, and Sandler, Howard M

Published
2022
Full Text
View/download PDF

16. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Author

Giri, Veda N, Knudsen, Karen E, Kelly, William K, Abida, Wassim, Andriole, Gerald L, Bangma, Chris H, Bekelman, Justin E, Benson, Mitchell C, Blanco, Amie, Burnett, Arthur, Catalona, William J, Cooney, Kathleen A, Cooperberg, Matthew, Crawford, David E, Den, Robert B, Dicker, Adam P, Eggener, Scott, Fleshner, Neil, Freedman, Matthew L, Hamdy, Freddie C, Hoffman-Censits, Jean, Hurwitz, Mark D, Hyatt, Colette, Isaacs, William B, Kane, Christopher J, Kantoff, Philip, Karnes, R Jeffrey, Karsh, Lawrence I, Klein, Eric A, Lin, Daniel W, Loughlin, Kevin R, Lu-Yao, Grace, Malkowicz, S Bruce, Mann, Mark J, Mark, James R, McCue, Peter A, Miner, Martin M, Morgan, Todd, Moul, Judd W, Myers, Ronald E, Nielsen, Sarah M, Obeid, Elias, Pavlovich, Christian P, Peiper, Stephen C, Penson, David F, Petrylak, Daniel, Pettaway, Curtis A, Pilarski, Robert, Pinto, Peter A, Poage, Wendy, Raj, Ganesh V, Rebbeck, Timothy R, Robson, Mark E, Rosenberg, Matt T, Sandler, Howard, Sartor, Oliver, Schaeffer, Edward, Schwartz, Gordon F, Shahin, Mark S, Shore, Neal D, Shuch, Brian, Soule, Howard R, Tomlins, Scott A, Trabulsi, Edouard J, Uzzo, Robert, Vander Griend, Donald J, Walsh, Patrick C, Weil, Carol J, Wender, Richard, and Gomella, Leonard G

Subjects
Humans, Prostatic Neoplasms, Genetic Predisposition to Disease, Prognosis, Risk Factors, Predictive Value of Tests, Pedigree, Age Factors, Heredity, Phenotype, Adult, Aged, Middle Aged, Male, Genetic Testing, Biomarkers, Tumor, Clinical Decision-Making, Genetics, Aging, Cancer, Prevention, Prostate Cancer, Urologic Diseases, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.

Published
2018

19. Preventing Prostate Biopsy Complications: to Augment or to Swab?

Author

Glick, Lydia, Vincent, Sage A., Squadron, Danielle, Han, Timothy M., Syed, Kanata, Danella, John F., Ginzburg, Serge, Guzzo, Thomas J., Lanchoney, Thomas, Raman, Jay D., Smaldone, Marc, Uzzo, Robert G., Tomaszweski, Jeffrey J., Reese, Adam, Singer, Eric A., Jacobs, Bruce, Trabulsi, Edouard J., Gomella, Leonard G., and Mann, Mark J.

Published
2021
Full Text
View/download PDF

25. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report

Author

Kim, Hyun, Alshalalfa, Mohammed, Hoffman-Censits, Jean, Lallas, Costas D, Davicioni, Elai, Lin, Jianqing, Birbe, Ruth, Erho, Nicholas, Lehrer, Jonathan, Ashab, Hussam Al-Deen, Takhar, Mandeep, Olson, Anders, Lam, Lucia LC, Kelly, W Kevin, Knudsen, Karen E, Thangavel, Chellappagounder, Seiler, Roland, Feng, Felix Y, Schaeffer, Edward M, Trabulsi, Edouard J, Gomella, Leonard G, Hurwitz, Mark D, Dicker, Adam P, and Den, Robert B

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Clinical Research, Health Services, Aging, Human Genome, Genetics, Urologic Diseases, Patient Safety, Clinical Trials and Supportive Activities, Prostate Cancer, Behavioral and Social Science, Biotechnology, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Prostate, Neuroendocrine, Genomics, Clinical sciences
Abstract

Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.

Published
2016

26. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy

Author

Marascio, Joseph, Spratt, Daniel E., Zhang, Jingbin, Trabulsi, Edouard J., Le, Tiffany, Sedzorme, Worlanyo Sosu, Beeler, Whitney H., Davicioni, Elai, Dabbas, Bashar, Lin, Daniel W., Gore, John L., Bloom, Matthew, Mann, Mark, Mark, J. Ryan, Calvaresi, Anne, Godwin, James L., McCue, Peter, Hurwitz, Mark D., Kelly, W. Kevin, Lallas, Costas D., Knudsen, Karen E., Gomella, Leonard G., Dicker, Adam P., and Den, Robert B.

Published
2020
Full Text
View/download PDF

27. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis

Author

Goodwin, Jonathan F, Kothari, Vishal, Drake, Justin M, Zhao, Shuang, Dylgjeri, Emanuela, Dean, Jeffry L, Schiewer, Matthew J, McNair, Christopher, Jones, Jennifer K, Aytes, Alvaro, Magee, Michael S, Snook, Adam E, Zhu, Ziqi, Den, Robert B, Birbe, Ruth C, Gomella, Leonard G, Graham, Nicholas A, Vashisht, Ajay A, Wohlschlegel, James A, Graeber, Thomas G, Karnes, R Jeffrey, Takhar, Mandeep, Davicioni, Elai, Tomlins, Scott A, Abate-Shen, Cory, Sharifi, Nima, Witte, Owen N, Feng, Felix Y, and Knudsen, Karen E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Genetics, Cancer, 2.1 Biological and endogenous factors, Animals, Cell Line, Tumor, DNA-Activated Protein Kinase, DNA-Binding Proteins, Gene Expression Regulation, Neoplastic, Gene Regulatory Networks, Humans, Male, Mice, Molecular Sequence Data, Neoplasm Invasiveness, Neoplasm Transplantation, Nuclear Proteins, Prostatic Neoplasms, Receptors, Androgen, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Emerging evidence demonstrates that the DNA repair kinase DNA-PKcs exerts divergent roles in transcriptional regulation of unsolved consequence. Here, in vitro and in vivo interrogation demonstrate that DNA-PKcs functions as a selective modulator of transcriptional networks that induce cell migration, invasion, and metastasis. Accordingly, suppression of DNA-PKcs inhibits tumor metastases. Clinical assessment revealed that DNA-PKcs is significantly elevated in advanced disease and independently predicts for metastases, recurrence, and reduced overall survival. Further investigation demonstrated that DNA-PKcs in advanced tumors is highly activated, independent of DNA damage indicators. Combined, these findings reveal unexpected DNA-PKcs functions, identify DNA-PKcs as a potent driver of tumor progression and metastases, and nominate DNA-PKcs as a therapeutic target for advanced malignancies.

Published
2015

33. A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III)

Author

Crawford, E. David, Koo, Phillip J., Shore, Neal, Slovin, Susan F., Concepcion, Raoul S., Freedland, Stephen J., Gomella, Leonard G., Karsh, Lawrence, Keane, Thomas E., Maroni, Paul, Penson, David, Petrylak, Daniel P., Ross, Ashley, Mouraviev, Vlad, Reiter, Robert E., Divgi, Chaitanya, and Yu, Evan Y.

Published
2018
Full Text
View/download PDF

38. The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)

Author

Crawford, E. David, Petrylak, Daniel P., Shore, Neal, Saad, Fred, Slovin, Susan F., Vogelzang, Nicholas J., Keane, Thomas E., Koo, Phillip J., Gomella, Leonard G., O'Sullivan, Joe M., Tombal, Bertrand, Concepcion, Raoul S., Sieber, Paul, Stone, Nelson N., Finkelstein, Steven E., and Yu, Evan Y.

Published
2017
Full Text
View/download PDF

41. Redefining Prostate Cancer Care: 'It's been an amazing 10 years'

Author

Gomella, Leonard G.

Subjects
Prostate cancer -- Care and treatment -- Genetic aspects, Cancer patients -- Care and treatment, Antineoplastic agents, Cancer -- Care and treatment, College teachers, Antimitotic agents, Health
Abstract

The past decade has seen a sea change in the treatment of prostate cancer. The implementation of genetic sequencing and the rise of targeted therapies have led to tailored treatment [...]

Published
2021

43. Supplementary Figures 1-9 from Dual Roles of PARP-1 Promote Cancer Growth and Progression

Author

Schiewer, Matthew J., primary, Goodwin, Jonathan F., primary, Han, Sumin, primary, Brenner, J. Chad, primary, Augello, Michael A., primary, Dean, Jeffry L., primary, Liu, Fengzhi, primary, Planck, Jamie L., primary, Ravindranathan, Preethi, primary, Chinnaiyan, Arul M., primary, McCue, Peter, primary, Gomella, Leonard G., primary, Raj, Ganesh V., primary, Dicker, Adam P., primary, Brody, Jonathan R., primary, Pascal, John M., primary, Centenera, Margaret M., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Feng, Felix Y., primary, and Knudsen, Karen E., primary

Published
2023
Full Text
View/download PDF

44. Data from Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia

Author

Liao, Zhiyong, primary, Gu, Lei, primary, Vergalli, Jenny, primary, Mariani, Samanta A., primary, De Dominici, Marco, primary, Lokareddy, Ravi K., primary, Dagvadorj, Ayush, primary, Purushottamachar, Puranik, primary, McCue, Peter A., primary, Trabulsi, Edouard, primary, Lallas, Costas D., primary, Gupta, Shilpa, primary, Ellsworth, Elyse, primary, Blackmon, Shauna, primary, Ertel, Adam, primary, Fortina, Paolo, primary, Leiby, Benjamin, primary, Xia, Guanjun, primary, Rui, Hallgeir, primary, Hoang, David T., primary, Gomella, Leonard G., primary, Cingolani, Gino, primary, Njar, Vincent, primary, Pattabiraman, Nagarajan, primary, Calabretta, Bruno, primary, and Nevalainen, Marja T., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 2 from Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia

Author

Liao, Zhiyong, primary, Gu, Lei, primary, Vergalli, Jenny, primary, Mariani, Samanta A., primary, De Dominici, Marco, primary, Lokareddy, Ravi K., primary, Dagvadorj, Ayush, primary, Purushottamachar, Puranik, primary, McCue, Peter A., primary, Trabulsi, Edouard, primary, Lallas, Costas D., primary, Gupta, Shilpa, primary, Ellsworth, Elyse, primary, Blackmon, Shauna, primary, Ertel, Adam, primary, Fortina, Paolo, primary, Leiby, Benjamin, primary, Xia, Guanjun, primary, Rui, Hallgeir, primary, Hoang, David T., primary, Gomella, Leonard G., primary, Cingolani, Gino, primary, Njar, Vincent, primary, Pattabiraman, Nagarajan, primary, Calabretta, Bruno, primary, and Nevalainen, Marja T., primary

Published
2023
Full Text
View/download PDF

48. Data from Dual Roles of PARP-1 Promote Cancer Growth and Progression

Author

Schiewer, Matthew J., primary, Goodwin, Jonathan F., primary, Han, Sumin, primary, Brenner, J. Chad, primary, Augello, Michael A., primary, Dean, Jeffry L., primary, Liu, Fengzhi, primary, Planck, Jamie L., primary, Ravindranathan, Preethi, primary, Chinnaiyan, Arul M., primary, McCue, Peter, primary, Gomella, Leonard G., primary, Raj, Ganesh V., primary, Dicker, Adam P., primary, Brody, Jonathan R., primary, Pascal, John M., primary, Centenera, Margaret M., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Feng, Felix Y., primary, and Knudsen, Karen E., primary

Published
2023
Full Text
View/download PDF

49. Supplemental Table 1 from Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia

Author

Liao, Zhiyong, primary, Gu, Lei, primary, Vergalli, Jenny, primary, Mariani, Samanta A., primary, De Dominici, Marco, primary, Lokareddy, Ravi K., primary, Dagvadorj, Ayush, primary, Purushottamachar, Puranik, primary, McCue, Peter A., primary, Trabulsi, Edouard, primary, Lallas, Costas D., primary, Gupta, Shilpa, primary, Ellsworth, Elyse, primary, Blackmon, Shauna, primary, Ertel, Adam, primary, Fortina, Paolo, primary, Leiby, Benjamin, primary, Xia, Guanjun, primary, Rui, Hallgeir, primary, Hoang, David T., primary, Gomella, Leonard G., primary, Cingolani, Gino, primary, Njar, Vincent, primary, Pattabiraman, Nagarajan, primary, Calabretta, Bruno, primary, and Nevalainen, Marja T., primary

Published
2023
Full Text
View/download PDF

50. Supplemental Table 3 from Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia

Author

Liao, Zhiyong, primary, Gu, Lei, primary, Vergalli, Jenny, primary, Mariani, Samanta A., primary, De Dominici, Marco, primary, Lokareddy, Ravi K., primary, Dagvadorj, Ayush, primary, Purushottamachar, Puranik, primary, McCue, Peter A., primary, Trabulsi, Edouard, primary, Lallas, Costas D., primary, Gupta, Shilpa, primary, Ellsworth, Elyse, primary, Blackmon, Shauna, primary, Ertel, Adam, primary, Fortina, Paolo, primary, Leiby, Benjamin, primary, Xia, Guanjun, primary, Rui, Hallgeir, primary, Hoang, David T., primary, Gomella, Leonard G., primary, Cingolani, Gino, primary, Njar, Vincent, primary, Pattabiraman, Nagarajan, primary, Calabretta, Bruno, primary, and Nevalainen, Marja T., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results